M-lucas is indicated for
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Montelukast is a selective leukotriene receptor antagonist (LTRA) that specifically inhibits the cysteinyl leukotriene receptor (CysLT1). Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are inflammatory mediators derived from arachidonic acid metabolism and are released by various immune cells, including mast cells and eosinophils.
These leukotrienes play a significant role in the pathophysiology of asthma and allergic rhinitis by:
✔ Inducing airway inflammation
✔ Causing smooth muscle contraction
✔ Increasing mucus production
✔ Triggering airway edema and bronchoconstriction
By blocking CysLT1 receptors, Montelukast effectively reduces inflammation and bronchial constriction, helping to control symptoms associated with asthma and allergic rhinitis.
🔹 Adults & Adolescents (15 years and older):
✔ Montelukast 10 mg tablet once daily in the evening.
🔹 Pediatric Patients:
✔ 6 to 14 years: Montelukast 5 mg tablet once daily.
✔ 2 to 5 years: Montelukast 4 mg tablet once daily.
✔ 6 months to 5 years: Montelukast 4 mg oral granules once daily.
Administration of Montelukast Oral Granules:
✔ No serious adverse effects reported in overdose cases.
✔ Common overdose symptoms:
✔ Management:
Montelukast (M-Lucas) has been used alongside other common asthma treatments without an increase in adverse reactions.
✔ No significant interaction was observed with:
✔ Safe concurrent use was also reported with:
✔ Caution is advised when co-administering Montelukast with:
🚫 Montelukast is contraindicated in patients with hypersensitivity to any of its components.
🔹 Common Side Effects:
🔹 Uncommon Side Effects:
🔹 Rare Side Effects:
✔ Montelukast crosses the placenta in animal studies (rats and rabbits), but no adequate human studies exist.
✔ Use only if clearly needed during pregnancy.
✔ Montelukast may be excreted in breast milk – caution is advised when prescribing to lactating mothers.
⚠ Not for acute asthma attacks – Montelukast is NOT a substitute for rescue inhalers. Patients should keep short-acting bronchodilators available.
⚠ Corticosteroid Tapering: Montelukast should not replace inhaled or oral corticosteroids abruptly – dose reduction should be gradual under medical supervision.
⚠ Not for monotherapy in exercise-induced bronchospasm – Should be used alongside other asthma medications.
⚠ Aspirin-Sensitive Asthma: Patients must continue avoiding NSAIDs & aspirin, as Montelukast does not prevent aspirin-induced bronchospasm.
Store below 30°C, in a cool, dry place, away from light and moisture.
Keep out of children’s reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.